secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001213900-22-035693
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium amends at-the-market sales agreement, adds B. Riley Securities as agent
--------------------------------------------------------------------------------

- Original Capital on Demand Sales Agreement (Aug 2020) allowed up to $200M in ATM offerings via JonesTrading.
- A&R Sales Agreement dated June 28, 2022 adds B. Riley Securities as an additional sales agent.
- No other material changes to terms; remaining $200M capacity unaffected.
- Agreement filed as Exhibit 1.1; representations are for parties only, not factual disclosures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022035693/0001213900-22-035693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022035693/ea161465-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-035693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer